Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 1.00 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714668 | 1.00 | CYP2B6 (1.00) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21327220 | 1.00 | CYP2B6 (1.00) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29714601 | 1.00 | CYP2B6 (1.00) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29714599 | 1.00 | CYP2B6 (1.00) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21327154 | 1.00 | CYP2B6 (1.00) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29714547 | 0.94 | CYP2B6 (0.88) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21327150 | 0.94 | CYP2B6 (0.88) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29050591 | 0.92 | CYP2B6 (0.85) | CYP2B6TENT4ATENT4B | |
| SCHEMBL29070749 | 0.92 | CYP2B6 (0.85) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21327140 | 0.91 | CYP2B6 (0.84) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505551-B2 | Methods for preparing substituted pyridinone-containing tricyclic compounds | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-11-22 | — | — | US | claimed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | claimed |
| CN-112839654-A | Process for preparing substituted pyridone-containing tricyclic compounds | 爱彼特生物制药公司 | 2021-05-25 | — | — | CN | claimed |
| US-20210032246-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-02-04 | — | — | US | claimed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | claimed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | claimed |
| US-20240052349-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11505551-B2 | Methods for preparing substituted pyridinone-containing tricyclic compounds | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-11-22 | — | — | US | disclosed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2020191207-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-24 | — | — | WO | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200109-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-17 | — | — | WO | disclosed |
| EP-3534903-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
| US-20240052349-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | SNRPE, AGO2, DCLRE1A | CYP2B6 4214/4885TENT4A 143/4885TENT4B 141/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
| US-11505551-B2 | Methods for preparing substituted pyridinone-containing tricyclic compounds | HMBS, TYMP, HAVCR2 | CYP2B6 18/4885TENT4A 93/4885TENT4B 183/4885 |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | HAVCR2, HDGF, FABP1 | CYP2B6 2860/4885TENT4A 1719/4885TENT4B 1090/4885 |
| US-20210032246-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | HMBS, TYMP, HAVCR2 | CYP2B6 18/4885TENT4A 93/4885TENT4B 183/4885 |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | CYP2B6 12/4885TENT4A 251/4885TENT4B 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.